GLMN/FAP48 Drug Discovery Landscape & Assay Solutions

  • By admin
  • 13 Aug 2026
  • Comments

Market Intelligence, Clinical Progress, and High-Purity Reagents for Vascular Malformation and Oncology Therapeutics Development.

TarMart Solution Ecosystem & Related Targets

Comprehensive reagent toolkit for GLMN drug discovery targeting glomuvenous malformations (GVM). Select your modality below:

Component / Network Product Description Product Link
Antigen (Wild Type) GLMN (FAP48) Full-Length Recombinant Protein
High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. HEK293 Expressed (Native Folding).		 View GLMN Products
Antigen (Disease Mutants) GLMN Pathogenic Variants (R395X, Q412X, W297R)
Loss-of-function mutants for GVM mechanism and chaperone screening. Theoretical MW verified.		 View GLMN Products
Gene Delivery GLMN ORF Lentivirus Particles
Full-length ORF for stable cell line construction in vascular endothelial models. High titer, Puromycin selectable.		 View GLMN Products
Validator GLMN siRNA Validation Set
For specific knockdown in functional rescue experiments and specificity controls.		 View GLMN Products
Direct Interactor RBX1 (RING-box Protein 1)
Critical GLMN binding partner; SCF E3 ubiquitin ligase RING component. Required for co-IP assays.		 View RBX1 Products
SCF Complex CUL1 (Cullin-1)
Scaffold protein of SCF complex; GLMN-mediated inhibition target. High purity for reconstitution studies.		 View CUL1 Products
Critical Assay Challenge The TarMart Advantage (Technical Spec)
Mutant Protein Stability Assessment (GVM variants often misfolded) GLMN Mutant Panel (R395X, Q412X) with Theoretical MW verification; HEK293 expressed for native folding analysis
GLMN-RBX1 Protein-Protein Interaction (PPI) Validation Full-length GLMN + RBX1 Co-expression System; Sequence Verified; Endotoxin Controlled for cellular assays
Intracellular Target Delivery (Gene therapy validation) High-titer GLMN Lentivirus Premade Particles; Puromycin selectable for stable vascular endothelial cell lines
Loss-of-Function Phenotype Modeling GLMN siRNA Set included for specificity controls; Compatible with rescue experiments using recombinant protein
SCF Complex Inhibition Assays Matched CUL1 and RBX1 recombinant proteins available for in vitro ubiquitination reconstitution

Live GLMN R&D Tracker

Market data changes daily. Access the latest global pipeline status directly:

Global Clinical Landscape & Future Outlook

The therapeutic landscape for GLMN-related glomuvenous malformations (GVM) remains in the early translational phase, dominated by academic research centers and rare disease biotechs. As an autosomal dominant vascular disorder caused by loss-of-function mutations in GLMN, traditional small molecule inhibition strategies are replaced by gene replacement and protein stabilization approaches. The current R&D focus has shifted toward AAV-mediated gene therapy delivery and pharmacological chaperones that restore mutant GLMN folding and RBX1 binding capacity. Originally identified for its role in glomuvenous malformations, GLMN is now recognized for its regulation of Cullin-RING ligases (CRLs) and interaction with FKBP12. As early-stage therapies move toward preclinical validation, the next wave of R&D is heavily focused on small molecule PPI inhibitors and targeted protein degraders (PROTACs) that modulate the GLMN-FKBP1A or GLMN-RBX1 axes.

Competitive Modality & Indication Snapshot

Modality Representative Players Key Indications Critical Assay Need (Why TarMart?)
Gene Therapy (AAV-GLMN) Academic Medical Centers, Rare Disease Biotechs Glomuvenous Malformations (GVM) Functional GLMN Expression Validation (Need high-purity GLMN antigen for ELISA/SPR quantification)
Pharmacological Chaperones Orphan Drug Developers GLMN Proteinopathies Mutant Protein Folding Rescue Assays (Need GLMN R395X/Q412X mutant proteins for thermal shift/SPR)
Protein Replacement Cell-Penetrating Peptide Biotechs Vascular Anomalies RBX1 Binding Affinity (Need native-folded GLMN for PPI assays)
Small Molecule SCF Modulators Targeted Protein Degradation Companies Oncology (indirect) SCF Complex Inhibition Assays (Need CUL1/RBX1/GLMN protein trio)

Key Mutations and Functional Implications

GLMN mutations are central to GVM pathology. Key variants include:

  • dbSNP:rs35258161: A missense mutation (UniProt VAR_061653) associated with altered protein function.
  • dbSNP:rs773442562: A mutation in GVMs leading to loss of interaction with CUL1 and RBX1 (UniProt VAR_017241), disrupting SCF complex regulation.

These mutations underscore the need for mutant-specific reagents in drug discovery.